Institut für Anorganische und Analytische Chemie, Goethe-Universität Frankfurt, Max-von-Laue-Strasse 7, D-60438 Frankfurt (Main), Germany.
Inorg Chem. 2010 Apr 5;49(7):3540-52. doi: 10.1021/ic100104t.
The coordination behavior, the conformational flexibility, and the stability of the novel (pyrazol-1-yl)borate ligands Ph(pz)B(mu-N(Me))(mu-pz)B(pz)Ph (L(1)), Ph(pz)B(mu-O)(mu-pz)B(pz)Ph (L(2)), and Ph(pz)B(mu-O)(mu-OB(Ph)O)B(pz)Ph (L(3)) have been experimentally assessed by investigating the following compounds: [Li(thf)L(1)], [Li(thf)L(2)], [Mg(Cl)(thf)(x)L(1)], [Mg(Cl)(thf)(2)L(2)], [Mn(CO)(3)L(2)], K(thf)[Mn(CO)(3)L(3)], [CoCl(2)(HL(1))], [L(1)Co(mu-Cl)(2)CoL(1)], [Zn(Br)L(1)], [Cu(Cl)L(1)], [Cu(Cl)L(2)]. The L(1)-complexes were prepared from a mixture of HL(1) and the appropriate metal salt by addition of a base. HCl elimination from [CoCl(2)(HL(1))], which gives [L(1)Co(mu-Cl)(2)CoL(1)], does not necessarily require the assistance of a base, but happens spontaneously when a solution of the complex is stored at room temperature for several days. K(thf)[Mn(CO)(3)L(3)] was obtained via in situ hydrolysis of HL(1)/[Mn(CO)(5)Br] in the presence of K(2)CO(3). In some other cases, formation of the coordination compounds proceeded with decomposition of a part of the ligand molecules and yielded pyrazole (e.g., [Zn(Cl)(Hpz)L(2)]) or pyrazolide (e.g., [L(2)Co(mu-Cl)(mu-pz)CoL(2)]) complexes. As evidenced by the crystal structure analyses of [Zn(Br)L(1)]/[Mg(Cl)(thf)(2)L(2)]/[Mn(CO)(3)L(2)] on the one hand and [L(1)Mg(mu-Cl)(2)Mg(thf)L(1)]/[Cu(Cl)L(1)]/Cu(Cl)L(2) on the other, L(1) and L(2) are able to adopt both a facial and a meridional conformation. Moreover, while many of the established design principles of scorpionate chemistry are still valid for L(1), L(2), and L(3), the bonding situation of the central donor moiety (N(Me) in L(1); O in L(2), L(3)) is distinctly different from the way the pyrazolyl rings are attached to the molecule, so that donor scrambling is not an issue in these [N,N,N] and [N,O,N] mixed-donor ligands.
新型(吡唑-1-基)硼酸酯配体 Ph(pz)B(mu-N(Me))(mu-pz)B(pz)Ph (L(1))、Ph(pz)B(mu-O)(mu-pz)B(pz)Ph (L(2)) 和 Ph(pz)B(mu-O)(mu-OB(Ph)O)B(pz)Ph (L(3)) 的配位行为、构象灵活性和稳定性已通过研究以下化合物得到实验评估:[Li(thf)L(1)]、[Li(thf)L(2)]、[Mg(Cl)(thf)(x)L(1)]、[Mg(Cl)(thf)(2)L(2)]、[Mn(CO)(3)L(2)]、K(thf)[Mn(CO)(3)L(3)]、[CoCl(2)(HL(1))]、[L(1)Co(mu-Cl)(2)CoL(1)]、[Zn(Br)L(1)]、[Cu(Cl)L(1)]、[Cu(Cl)L(2)]。L(1)-配合物是通过将 HL(1)与适当的金属盐混合,并加入碱来制备的。[CoCl(2)(HL(1))] 中的 HCl 消除不需要碱的帮助,但当该配合物的溶液在室温下储存数天时,会自发发生。K(thf)[Mn(CO)(3)L(3)] 通过 HL(1)/[Mn(CO)(5)Br] 在 K(2)CO(3)存在下的原位水解获得。在其他一些情况下,配位化合物的形成伴随着部分配体分子的分解,并生成吡唑(例如 [Zn(Cl)(Hpz)L(2)]) 或吡唑啉(例如 [L(2)Co(mu-Cl)(mu-pz)CoL(2)]) 配合物。一方面,[Zn(Br)L(1)]/[Mg(Cl)(thf)(2)L(2)]/[Mn(CO)(3)L(2)] 的晶体结构分析和另一方面 [L(1)Mg(mu-Cl)(2)Mg(thf)L(1)]/[Cu(Cl)L(1)]/Cu(Cl)L(2) 的晶体结构分析表明,L(1) 和 L(2) 都能够采用面式和轴向构象。此外,尽管蝎形配体化学的许多设计原则仍然适用于 L(1)、L(2) 和 L(3),但中心供体部分(L(1)中的 N(Me);L(2)和 L(3)中的 O)的键合情况与吡唑环连接到分子的方式明显不同,因此在这些[N,N,N]和[N,O,N]混合供体配体中不存在供体交换问题。